Remedica Limited initiates voluntary recall of Remethan 100mg tablets

Remedica Limited has announced a voluntary recall of specific batches of the anti-inflammatory drug Remethan 100mg prolonged-release tablets. The company stated this measure is strictly precautionary, following stability test results that fell outside of established specifications. The affected batches have expiration dates ranging from September 2026 to November 2030. Specifically, potential stock remains for batches numbered 116856, 122934, and 127806. Patients are advised to consult their doctors or pharmacists regarding alternative treatments. Remethan is a non-steroidal anti-inflammatory drug (NSAID) prescribed for managing pain, inflammation, and edema related to joint, muscle, and tendon conditions, as well as post-surgical recovery. The manufacturer emphasized that there is no immediate cause for concern at this time. Further updates or actions may follow pending the results of ongoing investigations.